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Abstract
Background: The Affymetrix GeneChip technology uses multiple probes per gene to measure its
expression level. Individual probe signals can vary widely, which hampers proper interpretation.
This variation can be caused by probes that do not properly match their target gene or that match
multiple genes. To determine the accuracy of Affymetrix arrays, we developed an extensive
verification protocol, for mouse arrays incorporating the NCBI RefSeq, NCBI UniGene Unique,
NIA Mouse Gene Index, and UCSC mouse genome databases.
Results: Applying this protocol to Affymetrix Mouse Genome arrays (the earlier U74Av2 and the
newer 430 2.0 array), the number of sequence-verified probes with perfect matches was no less
than 85% and 95%, respectively; and for 74% and 85% of the probe sets all probes were sequence
verified. The latter percentages increased to 80% and 94% after discarding one or two unverifiable
probes per probe set, and even further to 84% and 97% when, in addition, allowing for one or two
mismatches between probe and target gene. Similar results were obtained for other mouse arrays,
as well as for human and rat arrays. Based on these data, refined chip definition files for all arrays
are provided online. Researchers can choose the version appropriate for their study to (re)analyze
expression data.
Conclusion: The accuracy of Affymetrix probe sequences is higher than previously reported,
particularly on newer arrays. Yet, refined probe set definitions have clear effects on the detection
of differentially expressed genes. We demonstrate that the interpretation of the results of
Affymetrix arrays is improved when the new chip definition files are used.
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Background
Microarrays are widely used to study genome-wide gene
expression levels. A frequently used type of microarray is
the Affymetrix GeneChip [1]. This technology uses multi-
ple probes per gene (probe set) to measure the amount of
mRNA present (target). For reasons of specificity, probes
are chosen to be complementary to a unique part of the
target sequence. Although all probes from a single probe
set should measure the same amount of mRNA, the
hybridization signals of individual probes for a given
mRNA molecule may vary widely. This is believed to be
caused by variations in molecular characteristics of the
probe sequence, such as GC content and secondary struc-
ture, and corrections have been proposed to calculate true
expression levels averaged over probe signals [2,3]. How-
ever, another reason for the variation in signal between
probes could be misdesigned probes, that either do not
match the target RNA or can hybridize with other, non-
target, RNA molecules. For correct interpretation of the
results of Affymetrix GeneChip hybridizations, it is
important to know which probes may cause variation in
hybridization and for what reason. For example, in our
large scale genetical genomics applications [4-6], individ-
ual probe hybridizations are used to map regulatory
regions in a genome. In such applications, it is important
to be able to rule out potential false positive results due to
misdesigned probes.
An earlier analysis of the probe sequences of the Affyme-
trix mouse genome U74Av2 array [7] against the RefSeq
database showed that for only 51% of the probe sets on
the array all probes could be 'entirely verified', that is, cor-
responded without any mismatch to a RefSeq mRNA
sequence. A recent analysis at the individual probe level
verified 73% of the individual probe sequences of the
MG-U74Av2 array against mRNA sequences from Entrez
[8]. Affymetrix supplies regular updates of probe set veri-
fications using new releases of the RefSeq, GenBank and
Ensembl databases [9,10]. In the July 2006 release, 70%
of the probe sets of the MG-U74Av2 GeneChip are
'entirely verified'. These surprisingly low verification per-
centages suggest that a major part of the hybridization
results of such an array should be regarded with caution.
Little information is available on the possibility of hybrid-
ization of individual mouse probes with non-target RNA
molecules [8]. Here we present an extensive and general-
ized protocol for the verification of probe sequences on
Affymetrix arrays.
The protocol uses four databases: NCBI RefSeq, NCBI
UniGene Unique, NIA Mouse Gene Index, and UCSC
mouse genome. By incorporating these databases in the
verification protocol, the number of sequence-verified
probes of the Affymetrix mouse arrays increases consider-
ably. The same protocol applied to other mouse arrays, or
a similar protocol (based on RefSeq, UniGene Unique
and UCSC genome) for human and rat arrays, yielded
similar results. Refined chip definition files (CDF files),
which include only verified probes, are provided online.
We conclude that with the corrections as proposed previ-
ously [2,3], the accuracy and reliability of the Affymetrix
arrays is considerably higher than reported till now. Our
new data on probe verification and cross-hybridization
are important for assessing unexpected behaviour of any
given individual probe in a given experiment and will
contribute to the more accurate assessment of expression
data using Affymetrix arrays.
Results
Quality of sequence databases
The verification protocol for mouse arrays makes use of
three messenger databases (NCBI RefSeq, NCBI UniGene
Unique, NIA Mouse Gene Index), and one genome data-
base (UCSC mouse genome). We first assessed their qual-
ity. Assuming that the genome is the most accurate
sequence with an error rate of less than 1 in 10,000 bases
[11,12], we compared the sequence of 1000 randomly
selected genes, all occurring in each of the three messenger
databases, to the genome (see Methods). Table 1 shows
that there were no major quality differences between the
messenger databases, except that the NIA Mouse Gene
Index showed a lower mismatch frequency. The sequence
differences that are observed may be due to sequencing
errors, but also to genetic polymorphisms between mouse
strains. This means that each database contains reliable
information and can be used to verify probe sequences.
The verification protocol
In the protocol for mouse arrays, we use the BLAST pro-
gram to verify all probe sequences against the three mes-
senger databases (see Methods). Using the terminology of
Mecham et al. [7], for each probe set we determine per
database whether it is
• 'entirely verified', meaning that all probes were identical
to a messenger sequence;
￿ 'partially verified', meaning that only a subset of probes
was identical to a messenger sequence;
￿ 'entirely unverified', meaning that none of the probes
was identical to a messenger sequence.
Only probe sets that could not be classified as 'entirely
verified' against one of the three messenger databases,
were verified against the genome (see Methods). Each
probe set is assigned a verification score which is the best
score over all databases, where 'entirely verified' is better
than 'partially verified', and 'partially verified' is betterBMC Bioinformatics 2007, 8:132 http://www.biomedcentral.com/1471-2105/8/132
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than 'entirely unverified'. For the final verification score
the order of the databases does not matter since each
probe set is assigned the best possible score.
We included all mentioned databases in the protocol to
obtain the greatest coverage. Since the genome sequence
database is much larger than the messenger databases and
therefore the verification against the genome takes much
longer, we have put the verification against the genome in
the last position. This improves computational efficiency.
The verification is not hampered by the lower accuracy of
the messenger databases compared to the genome, since
only 0.60% (0.34%) of the probe sets of the MG-U74Av2
(430 2.0) array were 'entirely verified' against one of the
messenger databases but 'entirely unverified' against the
genome. We examined some of the probe sets that were
'entirely unverified' against the genome in more detail.
These seem to represent contaminated non-mouse
sequences, or the tiny fraction of genes that are still miss-
ing from the assembled genomes. Because there are no
major quality differences between the messenger data-
bases, their order is in principle arbitrary. However, we
have put RefSeq in the first position in the protocol since
it contains the most intensively curated transcript
sequence information and probe sets that are 'entirely ver-
ified' against this database exit the protocol with RefSeq
gene identifiers (supplementary material).
Verification of the U74 and 430 arrays
We here report the results of the application of the verifi-
cation protocol to two mouse GeneChips, MG-U74Av2
and 430 2.0, to which we will refer as 'U74' and '430',
respectively. The percentages of 'entirely verified' probe
sets are reported in a cumulative way, i.e. they grow with
every database added; see Figure 1.
Megablasting all probe sequences of the U74 array against
the mouse NCBI RefSeq database 'entirely verified' only
53% of all probe sets; this confirms the 51% reported ear-
lier [7] with an older version of the RefSeq database. From
the 430 array, only 46% of all probe sets could be 'entirely
verified' (Figure 1). Next, by including the UniGene
Unique database we 'entirely verified' 59% and 56% of all
probe sets in U74 and 430, respectively. Then, by includ-
ing the NIA Mouse Gene Index, the percentages grow to
69% and 74%, respectively. At last, we verified the
remaining probe sets that were not yet 'entirely verified'
against the UCSC mouse genome database. This way, we
finally 'entirely verified' 74% and 85% of all probe sets in
U74 and 430, respectively. More detailed numbers of the
contribution of each of the databases to the final verifica-
tion are given in additional file 1: 'Verification scores for
the Affymetrix U74 array' and additional file 2: 'Verifica-
tion scores for the Affymetrix 430 array'.
Most 'partially verified' probe sets contain at most two bad 
probes
In this verification protocol, the class 'partially verified' is
heterogeneous in nature. For a proper interpretation of
the hybridization signals of a given probe set, it may be
required to know how many and which probes of a partic-
ular set are not giving a perfect match with the mouse
genome data available. In Figure 2 we have plotted the
number of perfectly matching probes for those probe sets
that were categorized in the 'partially verified' class. This
shows that mainly one or two probes per probe set give a
less than perfect match. Especially in case of the U74
array, where 16 probes per gene are present, the hybridi-
zation results of such non-perfect probes could be disre-
garded and the remaining probe set can be considered
'entirely verified'. In the supplementary material, the pre-
cise identification of these probes can be retrieved. By
repeating the protocol and allowing one or two non-per-
fect probes per probe set, 80% and 94% of the probe sets
of U74 and 430 were 'entirely verified', respectively.
Allowing mismatches
Laboratory experience has shown that often the hybridiza-
tion conditions do not allow distinction between a perfect
match and a mismatch probe [13]. In this context, it could
be argued that the requirement for a perfect match in
probe sequence verification is not necessary, especially
when only PM signals are used for estimating the expres-
sion levels, as is the case for most modern probe summa-
rization methods (RMA, GCRMA). Moreover, messenger
databases contain sequencing errors. For these two rea-
sons, we have repeated the verification protocol as estab-
lished above while allowing either one or two mismatches
per probe sequence; 26% and 47% of the unverified
probes had one or two mismatches between probe and
Table 1: Comparison of sequence databases
Database No. of mismatches No. of gaps No. of nucleotides
RefSeq 2026 690 2291664
UniGene Unique 2076 717 2286979
NIA 337 703 1915516
Comparison with the genomic sequence of all entries of 1000 randomly selected genes that each has an entry in each of the three messenger 
databases. The summed number of mismatches, gaps and nucleotides for these 1000 genes is given.BMC Bioinformatics 2007, 8:132 http://www.biomedcentral.com/1471-2105/8/132
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target for U74 and 430, respectively. Figure 1 shows that
the percentage of 'entirely verified' probe sets increases
considerably, up to 77% for U74 and 91% for 430 in case
of one mismatch and up to 79% for U74 and 93% for 430
for two mismatches. If we restrict ourselves to probe sets
labeled by Affymetrix with "_at" then 85% of the probe
sets are 'entirely verified' for U74 and 92% for 430 in case
of one mismatch, and 87% for U74 and 93% for 430 for
two mismatches. If we allow for two mismatches and also
drop one or two unverifiable probes then 84% and 97%
of all probe sets of U74 and 430 were 'entirely verified'.
The hybridization conditions of the individual laboratory
will have to decide which validation scheme is most
appropriate and which probes or probe sets have to be
scrutinized with more care.
Cross-hybridization
Another issue of quality control is the specificity of probe
sequences. A probe set may be 'entirely verified' with a
given gene, yet an individual probe from such a set may
be identical, or more similar than desired, to the sequence
of another gene. This may cause cross-hybridization of
different mRNAs and give rise to a probe that yields a
hybridization signal that differs markedly from the other
probe sequences. For the U74 array, 17% of the probes in
'entirely verified' probe sets had more than one Megablast
Results of the verification protocol for the U74 and 430 arrays Figure 1
Results of the verification protocol for the U74 and 430 arrays. Three analyses were done per array: allowing only per-
fect matches, allowing one mismatch per probe and allowing two mismatches per probe. Per analysis, probe sets are assigned 
to the highest quality group (the lowermost group in the figure). So if a probe set is 'entirely verified' in RefSeq, it is assigned to 
this group. If it is not 'entirely verified' in RefSeq but it is 'entirely verified' in UniGene Unique, it is assigned to this second 
group, and so on.
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hit against the RefSeq, UniGene Unique and/or NIA data-
bases; 23% of the verified probe sets had at least one such
probe with multiple Megablast hits. For the 430 array the
percentages are 15% and 18% respectively. The numbers
of cross-hybridizing probes per verified probe set are
given in Figure 3. Note that the genome has not been used
to assess cross-hybridization, since probe selection
regions were used and individual probes were not com-
pared with the genome. In the majority of probe sets with
cross-hybridizing probes, all probes are cross-hybridizing.
This indicates different splicing variants or duplicated
genes that have different identifiers but can not be distin-
guished by these probe sets. Again, the individual labora-
tory will have to decide which probes or probe sets have
to be scrutinized with more care.
Verification of all available human, mouse and rat arrays 
confirms high probe accuracy
We applied the protocol to all other Affymetrix mouse
arrays and we developed a similar protocol consisting of
the three databases RefSeq, UniGene Unique and UCSC
genome for the analysis of all human and rat Affymetrix
arrays. Table 2 shows the results; the most striking obser-
vation is that, except the human X3P array, the newer
arrays show high accuracy of probe sequences. New chip
definition files for these 30 arrays can be downloaded
from [14]. One can choose CDF files with or without
cross-hybridizing probes and allowing for 0, 1 or 2 mis-
matches between sequence and probe.
The impact of updated probe set definitions on expression 
data
Microarrays are often used to find genes that are differen-
tially expressed. To assess the impact of the updated probe
set definitions on the assessment of differential gene
expression, we reanalyzed an example dataset, the Clinical
Prostate Cancer Behavior dataset (see Methods), consist-
ing of 52 prostate tumor RNA samples and 50 non-dis-
eased RNA samples hybridized to the human HG-U95Av2
array. Using RankProducts (Methods), we calculated lists
of differentially expressed genes, both using the original
Affymetrix CDF file and the new CDF file. 943 upregu-
lated probe sets were detected with both CDF files, 32
probe sets were detected only with the new CDF file and
41 probe sets were detected only with the original CDF file
(at a significance level of p < 0.05, Bonferroni adjused;
similar numbers were found for the downregulated
genes).
This result only shows that there are differences between
the two CDF files. To check if refining the probe set defi-
nition indeed improves  the results, we performed addi-
tional testing. For this purpose we focused on those genes
that are most strongly affected, i.e. those genes whose rank
in the list created with the original CDF file and the rank
in the list created with the new CDF file are most different.
Such genes will appear as differentially expressed in one
list but not the other. If random probes are different
between the two analyses, this difference can be both
Number of perfectly matching probes per probe set that are 'partially verified' against the genome Figure 2
Number of perfectly matching probes per probe set that are 'partially verified' against the genome. (A) for 3644 
probe sets of the U74 array; (B) for 10729 probe sets of the 430 array.
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ways, with equal probability. However, we predict that
improved probe sets will result in better detection of dif-
ferential expression, as non-verifiable probes probably do
not show differential expression and hence weaken the
differential expression of the whole probe set. In that case,
the genes that differ between the two lists should more
often be detected as differentially expressed with the new
CDF file compared to the original CDF file, than the other
way around. Focusing on the genes with the highest differ-
ences in ranks, a significant proportion (p < 1E-10; Wil-
coxon signed rank test) had a higher (better) rank in the
list created with the new CDF file compared to the list cre-
ated with the original CDF file (Table 3, columns a, b),
confirming our prediction. Of the 250 probesets that
showed the highest improvement in rank, 100% had been
redefined. This indicates that a significant number of
genes is picked up as differentially expressed with the new
CDF file, while they remain undetected using the original
CDF file.
To verify that this observed improvement of results is con-
sistent in other datasets and platforms, we repeated this
evaluation procedure for a dataset of 34 smoker vs. 23
non-smoker samples from intra-pulmonary airway epi-
thelial cells hybridized to HG-U133A arrays and a dataset
of 4 male vs. 4 female BWF1 lupus-prone mice spleen
samples hybridized to MG-U74Av2 arrays. We saw the
same clear improvement, with high statistical significance
(Table 3). As outlined above, we expect that random
changes in the probe set definition would lead to equal
numbers of genes being affected in either direction. We
calculated the difference of the observed amount of genes
having a higher rank with the new CDF and the expected
amount (n/2), for different values of n. We used the max-
imum excess as an estimate of the number of probe sets
that are significantly improved by refining the CDF files.
Depending on the array, these numbers range between
321 and 658. Although these numbers are small com-
pared to the total number of genes present on the array,
they comprise a large fraction of the genes that are typi-
cally found to be differentially expressed in a microarray
experiment.
Discussion
In different studies [7,8,15,16] Affymetrix probe
sequences were verified against mRNA databases. In all of
these studies, only one mRNA database was considered.
Gautier et al. [15] and Zhang et al. [16] verified human
Affymetrix arrays against mRNA sequences from Entrez
and RefSeq. Elo et al. [8] investigated the reproducibility
of the probe signals for different generations of Affymetrix
arrays. They compared the correlations of probe signals
for original Affymetrix probe sets and verified probe sets,
which they defined as the subset of probes of the original
probe sets that only match with the target transcript for
which the probes were originally designed by Affymetrix.
They found that probe verification improved the correla-
tions between generations of Affymetrix arrays and also
Number of cross-hybridizing probes per probe set for the 'entirely verified' probe sets Figure 3
Number of cross-hybridizing probes per probe set for the 'entirely verified' probe sets. (A) for 9184 probe sets of 
the U74 array; (B) for 38476 probe sets of the 430 array.
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that probe verification improved the consistency of the
measurements within an array. Mecham et al. [7] showed
that probe verification results in increased precision in
technical replicates; increased accuracy across comple-
mentary microarray platforms, increased accuracy trans-
lating data from oligonucleotide arrays to cDNA
microarrays, and increased diagnostic power of microar-
ray technology.
Table 2: Percentage of verified probe sets for all Affymetrix human, mouse and rat arrays analyzed
array (a) (b) (c) (d)
HC-G110 80 91 97 Feb 19, 2002
HG-Focus 86 97 99 Jul 02, 2002
HG-U133A 2.0 84 96 98 Nov 07, 2003
H G - U 1 3 3 A 8 49 69 8 F e b  1 9 ,  2 0 0 2
H G - U 1 3 3 B 8 09 69 8 F e b  1 9 ,  2 0 0 2
HG-U133 Plus 2.0 82 96 98 Nov 07, 2003
HG-U95Av2 84 93 97 Feb 19, 2002
HG-U95B 78 92 97 Feb 19, 2002
HG-U95C 71 85 93 Feb 19, 2002
HG-U95D 68 83 93 Feb 19, 2002
HG-U95E 71 86 93 Feb 19, 2002
HuGeneFL 68 84 94 Feb 19, 2002
H u m a n  X 3 P 2 02 52 6 J u l  1 9 ,  2 0 0 4
M G - U 7 4 A v 2 7 48 18 4 F e b  1 9 ,  2 0 0 2
M G - U 7 4 B v 2 7 18 38 7 F e b  1 9 ,  2 0 0 2
MG-U74Cv2 39 49 61 Feb 19, 2002
MOE-430A 90 95 97 Jun 18, 2003
MOE-430B 81 92 96 Jun 18, 2003
Mouse 430 2.0 85 94 97 May 25, 2004
Mouse 430A 2.0 90 95 97 Jun 18, 2003
M u 1 1 K - A 7 18 28 9 F e b  1 9 ,  2 0 0 2
M u 1 1 K - B 4 55 35 7 F e b  1 9 ,  2 0 0 2
RAE-230A 80 94 97 Jun 19, 2003
RAE-230B 69 89 94 Jun 19, 2003
Rat 230 2.0 64 89 93 Jul 20, 2004
RG-U34A 60 69 74 Feb 19, 2002
RG-U34B 20 28 33 Feb 19, 2002
RG-U34C 22 32 38 Feb 19, 2002
RN-U34 81 87 91 Feb 19, 2002
R T - U 3 4 6 67 37 9 F e b  1 9 ,  2 0 0 2
(a) all probe sequences are sequence verified; (b) all probes, except at most two per probe set, are sequence verified; (c) all probes, except at most 
two per probe set, are sequence verified allowing for one or two mismatches between probe and target gene; (d) date of release of the array.
Table 3: Comparison of lists of differentially expressed genes created with original and new CDF files.
Prostate Smokers Male/female
n Up Down Up Down Up Down
20 95% 100% 95% 100% 100% 100%
100 92% 97% 97% 99% 91% 98%
250 82% 94% 97% 92% 86% 95%
500 74% 86% 89% 84% 79% 86%
1000 55% 69% 78% 72% 75% 64%
2000 43% 48% 62% 52% 74% 54%
Two ranked lists of differentially expressed genes were calculated: one using Affymetrix' original CDF file and one using our CDF file. Genes were 
sorted in descending order according to their normalized difference in rank (|rank1–rank2|/minimum(rank1, rank2)). The top n genes are those 
which are most strongly affected by the probe set redefinition. The percentage of genes that obtained a higher rank using our refined CDF file 
compared to using the original CDF file is given. For random redefinitions, a percentage of 50 would be expected. Separate analyses for up- and 
downregulated genes were done. It can be seen that among the most strongly affected probe sets the large majority shows improved differential 
expression results when analyzed using the refined CDF file.BMC Bioinformatics 2007, 8:132 http://www.biomedcentral.com/1471-2105/8/132
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A problem with the RefSeq and the UniGene Unique data-
bases is that 3' UTRs are often truncated by the way the
sequences are assembled [17,18], while Affymetrix selects
the probes from the 600 bases most proximal to the 3' end
of each transcript [19]. We overcame this problem by
incorporating the genome in the verification protocol,
where all 3' UTRs are available.
The Fantom 3 project (Functional annotation of the
mouse, [20]) provides an extensive characterization of the
mouse transcriptome. We also tested the verification pro-
tocol with the Fantom 3 transcripts included. Since this
did not increase our verification scores (data not shown),
we did not include this database in our protocol.
The mRNA and genome databases currently available are
mainly based on the C57BL/6 mouse strain. Also, the
probes on the Affymetrix arrays are mainly based on the
C57BL/6 mouse strain. When samples from C57BL/6
mice are hybridized to the arrays, their transcripts are
expected to perfectly match the probes. However, mice
from genetically different strains or from recombinant
inbred pedigrees, as in our genetical genomics applica-
tions [4,6], may carry allelic SNPs compared to the
C57BL/6 genome. Probes carrying allelic SNPs may ham-
per data interpretation as putative differential mRNA
expression can be confounded with differential hybridiza-
tion [4]. When sequences of other mouse strains become
available, the verification protocol here developed should
be repeated for these newly sequenced strains to identify
and, if so desired, eliminate probes carrying allelic SNPs.
The use of refined probe set definitions, that exclude
unverified probes, will improve the interpretation of
expression data, as non-hybridizing and mis-hybridizing
probes add only noise to the data. Our evaluation of
expression data from the public domain shows that this is
indeed the case.
Conclusion
By combining various verifications as described above, we
show that 74% of the U74 probe sets and 85% of the 430
probe sets can be considered 'entirely verified' when based
on perfect matches. When two mismatches are allowed,
the percentages increase to 79% for U74 and 93% for 430.
When considering individual probes, 85% and 95% of the
probes were verified for U74 and 430 respectively, and
even 89% and 97% when allowing two mismatches. Our
extensive analyses of probe sequence data show that the
inclusion of various databases, such as the genome
sequence, indicate that the arrays are much more accurate
than shown previously. Existing data can be reanalyzed
with our verified probe sets (using the online CDF files).
We show that such a refined probe set definition has clear
effects on the detection of differentially expressed genes
and demonstrate for various experiments that the results
are systematically improved by discarding unverified
probes.
Methods
Affymetrix GeneChips
Probe set annotations and probe selection regions (PSR)
for all human, mouse and rat arrays, were obtained from
Affymetrix [9,10].
The U74Av2 array is based on the mouse UniGene data-
base, release 74. It contains 196.670 oligomers of length
25, divided into 12.422 probe sets, most of which contain
16 oligomers. Probe sets of the newer 430 2.0 array were
selected from sequences derived from dbEST (NCBI, June
2002), GenBank (NCBI, Release 129, April 2002), and
RefSeq (NCBI, June 2002) [21]. It contains 495.374 oli-
gomers of length 25, divided into 45.037 probe sets, gen-
erally consisting of 11 oligomers.
Sequence databases
RefSeq is a curated non-redundant collection of naturally
occurring DNA, RNA and protein sequences. It is based on
the sequences and annotations supplied to GenBank by
the original researchers [17]. For mouse we used 55,810
messenger sequences from RefSeq.
UniGene is a processed and curated collection of millions
of ESTs (Expressed Sequence Tags), which are relatively
inaccurate (around 2% error). To assign ESTs to genes, the
ESTs are clustered and the cluster consensus sequences
stored in UniGene Unique [18]. The mouse UniGene
Unique release contains 43,104 sequences.
NIA Mouse Gene Index (developed by the National Insti-
tute on Aging) is currently the most comprehensive collec-
tion of alternative transcription/splicing sequences.
Patterns of alternative transcription/splicing are obtained
by aligning a complete and nonredundant transcriptome
assembly from expressed sequences (obtained from Ref-
Seq, GenBank, dbEST, Ensembl and NIA) to the mouse
genome [22]. The NIA Mouse Gene Index contains
186,405 sequences.
The UCSC mouse genome (maintained by University of
California Santa Cruz) reports about 90% of the genome
in finished form (error rate of less than 1 in 10,000 bases).
We used build mm7 (corresponding to NCBI build 35.1;
August, 2005).
For the mouse protocol we used two NCBI [23] databases:
RefSeq mRNAs (NCBI, Feb. 3, 2006) and UniGene
Unique (NCBI, build 151, Oct. 20, 2005). In addition, we
used all mouse mRNA sequences from the National Insti-
tute on Aging (NIA Mouse Gene Index 5, June 2005, [22])BMC Bioinformatics 2007, 8:132 http://www.biomedcentral.com/1471-2105/8/132
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and the UCSC mouse genome (mm7, Aug. 2005, [11]).
For the human protocol we used RefSeq mRNAs (NCBI,
Feb. 16, 2006), UniGene Unique (NCBI, build 188, Dec.
30, 2005) and UCSC human genome (hg17, May 2004).
For the rat protocol we used RefSeq mRNAs (NCBI, Feb.
16, 2006), UniGene Unique (NCBI, build 149, Jan. 25,
2006) and UCSC rat genome (rn3, June 2003).
Assessment of the quality of the sequence databases
To assess the quality of the sequence databases, we took
the UCSC genome sequence as a reference, and compared
the sequences of 1000 randomly selected genes, all occur-
ring in each of the three messenger databases, to the
genome sequence. Since the genome contains introns and
the messenger databases do not, we extracted the exon
sequences from the genome by using the exon coordinates
of RefSeq genes and attached them to each other. Then for
each of the 1000 genes we compared the three messenger
sequences to the reconstructed genome sequence and
counted the amounts of mismatches and gaps (Table 1).
Sequence alignment algorithms
Individual probes were analyzed against the messenger
databases with Megablast (version 2.2.6 with a word size
of 12, [24]) for 'short nearly exact matches'. Hits in data-
bases were distinguished on the basis of none, one or two
mismatches with the probe sequence.
Since analysis of all single probe sequences against the
mouse genome gives too many non-exon hits (data not
shown), we used the probe selection region (PSR) of each
probe set as input for BLAT ([11], standalone BLAT ver-
sion 32 × 1, standard settings). PSR is defined as the
unique part of the messenger sequence from which
Affymetrix selected the probes [19]. We masked all nucle-
otides not represented in probe sequences. Within the
obtained BLAT hits of the masked PSRs, we re-identified
the position of each probe to count the number of mis-
matches per probe.
Computing infrastructure
All analyses were performed on a Linux cluster consisting
of 200 nodes with dual Opteron processors 2 GHz and 1
GB memory. The average computation time per array was
4 hours on one node.
Datasets and methods for determining the impact of 
updated probe set definitions on expression data
The Clinical Prostate Cancer Behavior dataset was down-
loaded from [25]. The smoker vs. non-smoker dataset was
downloaded from the Gene Expression Omnibus (GEO)
and has accession number GSE994. The male vs. female
BWF1 lupus-prone mice dataset was also downloaded
from GEO (accession number GSE2336). In all cases we
used RMA [26] to generate probe set-level data. Using
RankProducts [27] we calculated ranked lists of differen-
tially expressed genes using Affymetrix' original CDF file
and our refined CDF file, while separating up- and down-
regulated genes.
Authors' contributions
RA was responsible for designing and implementing the
protocol, interpreting the data, writing and finalizing the
paper. PT helped in the design of the protocol, supervised
the implementation and contributed to the interpretation
of the data and writing the paper. MH participated in the
implementation of the protocol. LVB helped with the bio-
logical interpretation of the results. GdH participated in
writing the paper. RB participated in determining the
impact of updated chip definition files on expression data
and finalization of the manuscript. JPN drafted the man-
uscript, helped with the interpretation of the data and
contributed to the finalization of the manuscript. RCJ
conceived the study of individual Affymetrix probes, coor-
dinated the study and the writing and was responsible for
the funding. All authors read and approved the final man-
uscript.
Additional material
Acknowledgements
RA was supported by Biomolecular Informatics grant 050-50-203 from the 
Netherlands Organisation for Scientific Research (NWO).
LVB was supported by the Dutch Cancer Society and by the US National 
Institutes of Health.
References
1. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS,
Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL: Expres-
sion monitoring by hybridization to high-density oligonucle-
otide arrays.  Nat Biotechnol 1996, 14:1675-1680.
Additional File 1
Verification scores for the Affymetrix U74 array. The file contains the 
numbers and percentages of probe sets per occurring combination of veri-
fication scores. 'e' = 'entirely verified', 'p' = 'partially verified' and 'u' = 
'entirely unverified'.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-132-S1.xls]
Additional File 2
Verification scores for the Affymetrix 430 array. The file contains the 
numbers and percentages of probe sets per occurring combination of veri-
fication scores. 'e' = 'entirely verified', 'p' = 'partially verified' and 'u' = 
'entirely unverified'.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-8-132-S2.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Bioinformatics 2007, 8:132 http://www.biomedcentral.com/1471-2105/8/132
Page 10 of 10
(page number not for citation purposes)
2. Zhang L, Miles MF, Aldape KD: A model of molecular interac-
tions on short oligonucleotide microarrays.  Nat Biotechnol
2003, 21:818-821.
3. Wu Z, Irizarry RA: Preprocessing of oligonucleotide array
data.  Nat Biotechnol 2004, 22:656-658.
4. Alberts R, Terpstra P, Bystrykh LV, de Haan G, Jansen RC: A statis-
tical multiprobe model for analyzing cis and trans genes in
genetical genomics experiments with short-oligonucleotide
arrays.  Genetics 2005, 171:1437-1439.
5. Jansen RC, Nap JP: Genetical genomics: the added value from
segregation.  Trends Genet 2001, 17:388-391.
6. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, Wiltshire
T, Su AI, Vellenga E, Wang J, Manly KF, Lu L, Chesler EJ, Alberts R,
Jansen RC, Williams RW, Cooke MP, de Haan G: Uncovering reg-
ulatory pathways that affect hematopoietic stem cell func-
tion using 'genetical genomics'.  Nat Genet 2005, 37:225-232.
7. Mecham BH, Wetmore DZ, Szallasi Z, Sadovsky Y, Kohane I, Mariani
TJ: Increased measurement accuracy for sequence-verified
microarray probes.  Physiol Genomics 2004, 18:308-315.
8. Elo LL, Lahti L, Skottman H, Kylaniemi M, Lahesmaa R, Aittokallio T:
Integrating probe-level expression changes across genera-
tions of Affymetrix arrays.  Nucleic Acids Res 2005, 33:e193.
9. NetAffx Analysis Center: Affymetrix.  2006 [http://www.affyme
trix.com/analysis/index.affx].
10. Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S,
Kulp D, Siani-Rose MA: NetAffx: Affymetrix probesets and
annotations.  Nucleic Acids Res 2003, 31:82-86.
11. UCSC Genome Browser  2006 [http://genome.ucsc.edu].
12. Genome Glossary  2006 [http://www.ncbi.nlm.nih.gov/genome/
guide/glossary.htm].
13. Naef F, Magnasco MO: Solving the riddle of the bright mis-
matches: labeling and effective binding in oligonucleotide
arrays.  Phys Rev E Stat Nonlin Soft Matter Phys 2003, 68:011906.
14. GBiC supplementary data  2006 [http://gbic.biol.rug.nl/supple
mentary/2006/probeverification].
15. Gautier L, Moller M, Friis-Hansen L, Knudsen S: Alternative map-
ping of probes to genes for Affymetrix chips.  BMC Bioinformat-
ics 2004, 5:111.
16. Zhang J, Finney RP, Clifford RJ, Derr LK, Buetow KH: Detecting
false expression signals in high-density oligonucleotide
arrays by an in silico approach.  Genomics 2005, 85:297-308.
17. Pruitt K, Tatusova T, Ostell J: The Reference Sequence (RefSeq)
Project.  In The NCBI Handbook Edited by: McEntyre J and Ostell J.
Bethesda (MD), National Library of Medicine; 2002:18-1-18-20. 
18. Pontius JU, Wagner L, Schuler GD: UniGene: A Unified View of
the Transcriptome.  In The NCBI Handbook Edited by: McEntyre J
and Ostell J. Bethesda (MD), National Library of Medicine; 2002:21-
1-21-12. 
19. Affymetrix Technical Note  2006 [http://www.affymetrix.com/
support/technical/technotes/mouse430_technote.pdf].
20. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N,
Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K,
Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ,
Wilming LG, Aidinis V, Allen JE, mbesi-Impiombato A, Apweiler R,
Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T,
Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutter-
buck DR, Crowe ML, Dalla E, Dalrymple BP, de BB, Della GG, di BD,
Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima
T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR,
Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch
TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A,
Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kita-
mura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK,
Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWil-
liam S, Madan BM, Madera M, Marchionni L, Matsuda H, Matsuzawa S,
Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N,
Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S,
Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi
G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald
M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schonbach
C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shi-
mada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K,
Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS,
Tegner J, Teichmann SA, Ueda HR, van NE, Verardo R, Wei CL, Yagi
K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C,
Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahl-
estedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S,
Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura
K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M,
Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M,
Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki
A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y: The tran-
scriptional landscape of the mammalian genome.  Science
2005, 309:1559-1563.
21. Affymetrix Data Sheet   [http://www.affymetrix.com/support/
technical/datasheets/mogarrays_datasheet.pdf]
22. Sharov AA, Dudekula DB, Ko MS: Genome-wide assembly and
analysis of alternative transcripts in mouse.  Genome Res 2005,
15:748-754.
23. NCBI HomePage  2006 [http://www.ncbi.nlm.nih.gov].
24. Zhang Z, Schwartz S, Wagner L, Miller W: A greedy algorithm for
aligning DNA sequences.  J Comput Biol 2000, 7:203-214.
25. Cancer Program Data Sets  2006 [http://www.broad.mit.edu/cgi-
bin/cancer/datasets.cgi].
26. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP:
Summaries of Affymetrix GeneChip probe level data.  Nucleic
Acids Res 2003, 31:e15.
27. Breitling R, Armengaud P, Amtmann A, Herzyk P: Rank products: a
simple, yet powerful, new method to detect differentially
regulated genes in replicated microarray experiments.  FEBS
Lett 2004, 573:83-92.